| Brian J Mcmanus, MD | |
|
110 Long Pond Rd, Suite 212, Plymouth, MA 02360-2642 | |
| (508) 746-7272 | |
| (508) 746-0104 |
| Full Name | Brian J Mcmanus |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 26 Years |
| Location | 110 Long Pond Rd, Plymouth, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1669585899 | NPI | - | NPPES |
| 2067081 | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 220157 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bayada Home Health Care Inc | Plymouth, MA | Home health agency |
| Beth Israel Deaconess Hospital Plymouth | Plymouth, MA | Hospital |
| Massachusetts General Hospital | Boston, MA | Hospital |
| Southcoast Hospitals Group | Fall river, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Plymouth Carver Primary Care, P.c. | 3173573037 | 5 |
News Archive
Many companies in the cell therapy regenerative medicine market including Roche, Genzyme, Athersys, Miltenyi Biotec, Hospira, Lonza and Life Technologies will join ISCT to launch a series of new initiatives that will create greater strategic alignment within the industry and drive late stage clinical development.
Boehringer Ingelheim will present a pooled analysis of new data from the Phase 3 UniTinA-asthma® program at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona. The data from the individual MezzoTinA-asthma® Phase 3 studies (NCT01340209 and NCT00565266), from which the pooled data are derived, show the addition of tiotropium delivered via the Respimat® inhaler to medium-dose maintenance inhaled corticosteroid (ICS) therapy (defined as 400-800 µg budesonide/day or equivalent) improved lung function and provided sustained bronchodilation over 24 hours in patients with moderate asthma and airflow limitation. Tiotropium is being investigated to determine the medicine's efficacy in treating asthma patients and is not currently approved for this indication.
Scientists at Cold Spring Harbor Laboratory and Stanford University have pinpointed the circuit in the brain that is responsible for sleepless nights in times of stress-and it turns out that circuit does more than make you toss and turn.
Using a computational model of addiction, a literature review and an in silico experiment, theoretical computer scientist Yariv Levy and colleagues suggest in a new paper this week that rehabilitation strategies coupling meditation-like practices with drug and behavior therapies are more helpful than drug-plus-talk therapy alone when helping people overcome addiction.
› Verified 8 days ago
| Entity Name | Plymouth Carver Primary Care, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285761619 PECOS PAC ID: 3173573037 Enrollment ID: O20050127000931 |
News Archive
Many companies in the cell therapy regenerative medicine market including Roche, Genzyme, Athersys, Miltenyi Biotec, Hospira, Lonza and Life Technologies will join ISCT to launch a series of new initiatives that will create greater strategic alignment within the industry and drive late stage clinical development.
Boehringer Ingelheim will present a pooled analysis of new data from the Phase 3 UniTinA-asthma® program at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona. The data from the individual MezzoTinA-asthma® Phase 3 studies (NCT01340209 and NCT00565266), from which the pooled data are derived, show the addition of tiotropium delivered via the Respimat® inhaler to medium-dose maintenance inhaled corticosteroid (ICS) therapy (defined as 400-800 µg budesonide/day or equivalent) improved lung function and provided sustained bronchodilation over 24 hours in patients with moderate asthma and airflow limitation. Tiotropium is being investigated to determine the medicine's efficacy in treating asthma patients and is not currently approved for this indication.
Scientists at Cold Spring Harbor Laboratory and Stanford University have pinpointed the circuit in the brain that is responsible for sleepless nights in times of stress-and it turns out that circuit does more than make you toss and turn.
Using a computational model of addiction, a literature review and an in silico experiment, theoretical computer scientist Yariv Levy and colleagues suggest in a new paper this week that rehabilitation strategies coupling meditation-like practices with drug and behavior therapies are more helpful than drug-plus-talk therapy alone when helping people overcome addiction.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brian J Mcmanus, MD 110 Long Pond Rd, Suite 212, Plymouth, MA 02360-2642 Ph: (508) 746-7272 | Brian J Mcmanus, MD 110 Long Pond Rd, Suite 212, Plymouth, MA 02360-2642 Ph: (508) 746-7272 |
News Archive
Many companies in the cell therapy regenerative medicine market including Roche, Genzyme, Athersys, Miltenyi Biotec, Hospira, Lonza and Life Technologies will join ISCT to launch a series of new initiatives that will create greater strategic alignment within the industry and drive late stage clinical development.
Boehringer Ingelheim will present a pooled analysis of new data from the Phase 3 UniTinA-asthma® program at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona. The data from the individual MezzoTinA-asthma® Phase 3 studies (NCT01340209 and NCT00565266), from which the pooled data are derived, show the addition of tiotropium delivered via the Respimat® inhaler to medium-dose maintenance inhaled corticosteroid (ICS) therapy (defined as 400-800 µg budesonide/day or equivalent) improved lung function and provided sustained bronchodilation over 24 hours in patients with moderate asthma and airflow limitation. Tiotropium is being investigated to determine the medicine's efficacy in treating asthma patients and is not currently approved for this indication.
Scientists at Cold Spring Harbor Laboratory and Stanford University have pinpointed the circuit in the brain that is responsible for sleepless nights in times of stress-and it turns out that circuit does more than make you toss and turn.
Using a computational model of addiction, a literature review and an in silico experiment, theoretical computer scientist Yariv Levy and colleagues suggest in a new paper this week that rehabilitation strategies coupling meditation-like practices with drug and behavior therapies are more helpful than drug-plus-talk therapy alone when helping people overcome addiction.
› Verified 8 days ago
Gregory Joseph Robke, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 45 Resnik Road, Suite 302, Plymouth, MA 02360 Phone: 508-746-2696 Fax: 508-746-2695 | |
Dr. Irina Gurevich, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 275 Sandwich St, C/o Cathy Grey, Plymouth, MA 02360 Phone: 508-830-2390 Fax: 508-830-2399 | |
Maysaa El Zoghbi, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 275 Sandwich St, Plymouth, MA 02360 Phone: 508-746-2000 | |
Baigalmaa Enkhtaivan, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 275 Sandwich St, Plymouth, MA 02360 Phone: 508-830-2679 Fax: 508-830-2702 | |
Senada Arabelovic, DO Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 45 Resnik Rd, Plymouth, MA 02360 Phone: 508-746-5351 | |
Muhammad Mubarak, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 275 Sandwich St, Plymouth, MA 02360 Phone: 617-754-4677 | |
Katherine Murray Leisure, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 116 Court St, 3rd Floor, Plymouth, MA 02360 Phone: 508-746-2138 Fax: 508-746-2148 |